Publisher： John Wiley & Sons Inc
E-ISSN： 2050-0904|3|10|790-792
ISSN： 2050-0904
Source： Clinical Case Reports, Vol.3, Iss.10, 2015-10, pp. : 790-792
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Key Clinical MessageThe new direct oral anticoagulants such us rivaroxaban, could play an important role in the anticoagulant treatment of patients with paroxysmal nocturnal hemoglobinuria where anticoagulant treatment is complex to run, since they have shown a reduction in serious bleeding complications compared to antithrombotic therapy with classical vitamin k antagonist.
Related content
Access to resources
Recommend
